This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Evidence-Based Medicine  • Neoplasms  • Diagnosis  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

Matthew H. Kanzler, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

I am glad that my editorial elicited such a passionate response from Cochran and Thompson. Education is achieved only through an exchange of ideas.

We always advise our dermatology residents and medical students to use a newly proposed therapy quickly before its efficacy is disproved by prospective trials! Such was the case with elective lymph node dissections for patients with melanoma a few decades ago, until prospective trials failed to confirm the expected therapeutic benefit of these procedures. Such is also the case with the therapeutic role of SNB procedures for melanoma today. The recent MSLT-1 Trial¹ finally has given us evidence that the procedure does not improve overall survival for patients who undergo the procedure compared with patients who do not undergo the procedure.

Unfortunately, in their letter, Cochran and Thompson simply restate many of the erroneous conclusions presented in the initial MSLT-1 . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Kaposi’s Sarcoma Resolves After Sirolimus Therapy in a Patient With Pemphigus Vulgaris
Sarika Saggar, Joshua A. Zeichner, Tamu T. Brown, Robert G. Phelps, and Steven R. Cohen
Arch Dermatol. 2008;144(5):654-657.
ABSTRACT | FULL TEXT